- Open
- 74.40
- High
- 74.40
- Low
- 74.32
- Close
- 74.32
- Change
- -1.50 (-2.04%)
- Volume
- 219,766
| 30 Sept 2026 | 16:33:18 | Dividend Declaration |
| 30 Sept 2026 | 16:21:53 | Director/PDMR Shareholding |
| 24 Sept 2026 | 07:00:07 | Half-year Financial Report |
| 23 Sept 2026 | 16:00:00 | Net Asset Value(s) and Monthly Factsheet |
| 25 Mar 2026 | Annual Report and Financial Statements for the year ended 31 December 2025 | |
| 1 Jan 2026 | Annual_Report_2025 | |
| 10 Apr 2025 | Annual Financial Report |
BioPharma Credit PLC specializes in providing debt financing to companies within the life sciences sector. It primarily invests in corporate and royalty debt secured by cash flows from the sales of approved life sciences products. The trust aims to generate long-term shareholder returns, predominantly through sustainable income distributions. Managed by Pharmakon Advisors, BioPharma Credit focuses on building a diversified portfolio with a strong emphasis on cash flow visibility and stability.
| 30 Sept 2026 | 16:33:18 | Dividend Declaration |
| 30 Sept 2026 | 16:21:53 | Director/PDMR Shareholding |
| 24 Sept 2026 | 07:00:07 | Half-year Financial Report |
| 23 Sept 2026 | 16:00:00 | Net Asset Value(s) and Monthly Factsheet |
| 25 Mar 2026 | Annual Report and Financial Statements for the year ended 31 December 2025 | |
| 1 Jan 2026 | Annual_Report_2025 | |
| 10 Apr 2025 | Annual Financial Report |
BioPharma Credit PLC specializes in providing debt financing to companies within the life sciences sector. It primarily invests in corporate and royalty debt secured by cash flows from the sales of approved life sciences products. The trust aims to generate long-term shareholder returns, predominantly through sustainable income distributions. Managed by Pharmakon Advisors, BioPharma Credit focuses on building a diversified portfolio with a strong emphasis on cash flow visibility and stability.
| 23 Sept 2026 |
| 12:17:18 |
| Holding(s) in Company |
| 6 May 2026 |
| Morning briefing: Will Morgan joins Foresight Solar; Brett Miller resigns from Achilles; Target Healthcare sells home in arrears; Geiger sets next subscription price; ASLI agrees penultimate disposal |
| 3 May 2026 | How hedge funds can help you invest like the 1% |
| 24 Mar 2026 | Higher-for-longer interest rates benefit 10%-yielding BioPharma Credit as loan fund reinvests $422m cash |
| 17 Mar 2026 | Morning briefing: Geiger Counter serves notice on Manulife; Government delays Tritax data centre decision; plus BPCR, OCI, PCTN, ASLI |
| 23 Sept 2026 |
| 12:17:18 |
| Holding(s) in Company |
| 6 May 2026 |
| Morning briefing: Will Morgan joins Foresight Solar; Brett Miller resigns from Achilles; Target Healthcare sells home in arrears; Geiger sets next subscription price; ASLI agrees penultimate disposal |
| 3 May 2026 | How hedge funds can help you invest like the 1% |
| 24 Mar 2026 | Higher-for-longer interest rates benefit 10%-yielding BioPharma Credit as loan fund reinvests $422m cash |
| 17 Mar 2026 | Morning briefing: Geiger Counter serves notice on Manulife; Government delays Tritax data centre decision; plus BPCR, OCI, PCTN, ASLI |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £1.42bn | +0.2% | |
BPCPBiopharma Credit PLC | £1.02bn | +0.1% |
| £843m | -0.0% | |
| £834m | +0.2% | |
| £802m | +0.2% | |
| £180m | +0.4% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £1.42bn | +0.2% | |
BPCPBiopharma Credit PLC | £1.02bn | +0.1% |
| £843m | -0.0% | |
| £834m | +0.2% | |
| £802m | +0.2% | |
| £180m | +0.4% |